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We estimated direct medical and nonmedical costs associated with a false diagnosis of tuberculosis (TB)
caused by laboratory cross-contamination of Mycobacterium tuberculosis cultures in Massachusetts in
1998 and 1999. For three patients who received misdiagnoses of active TB disease on the basis of labora-
tory cross-contamination, the costs totaled U.S.$32,618. Of the total, 97% was attributed to the public sec-
tor (local and state health departments, public health hospital and laboratory, and county and state
correctional facilities); 3% to the private sector (physicians, hospitals, and laboratories); and <1% to the
patient. Hospitalizations and inpatient tests, procedures, and TB medications accounted for 69% of costs,
and outpatient TB medications accounted for 18%. The average cost per patient was $10,873 (range,
$1,033–$21,306). Reducing laboratory cross-contamination and quickly identifying patients with cross-
contaminated cultures can prevent unnecessary and potentially dangerous treatment regimens and
anguish for the patient and financial burden to the health-care system.
o date, studies investigating cases of laboratory cross-con-
tamination have described only the resources to care for
patients who received false diagnoses of tuberculosis (TB) (1–
6); to our knowledge, the costs attributable to cross-contami-
nation have not been reported. We estimated direct medical
and nonmedical costs for three patients whose misdiagnoses of
active TB disease resulted from laboratory cross-contamina-
tion of Mycobacterium tuberculosis cultures. The costs totaled
U.S.$32,618. By examining the costs from the perspective of
the patient and the public and private sectors, we documented
the financial costs to the health-care system caused by labora-
tory cross-contamination.
The rate of patients having false-positive M. tuberculosis
cultures resulting from laboratory cross-contamination may be
up to 33% of culture-confirmed TB patients (1–3,7–11).
Reportedly two thirds of patients with false-positive cultures
are treated for active TB disease (4) and may undergo unnec-
essary, potentially toxic anti-TB therapy. Public health depart-
ments may initiate costly activities such as contact
investigations and directly observed therapy. Dunlap et al.
report that if persons who receive misdiagnoses resulting from
laboratory cross-contamination were treated as TB case-
patients with contact investigations and 6 months of directly
observed therapy, the costs to the health-care system would be
$2,500 per patient (12) in 1993 U.S. dollars, or $3,111 in 1999
dollars, when the Medical Care component of the Consumer
Price Index is used to convert 1993 dollars to 1999 dollars. 
Methods
Identifying Patients
As part of the Centers for Disease Control and Prevention–
funded National Tuberculosis Genotyping and Surveillance
Network, the Massachusetts Department of Public Health,
Division of Tuberculosis Prevention and Control (TB Divi-
sion), conducted a population-based study to determine the
rate of TB misdiagnosis in Massachusetts caused by laboratory
cross-contamination of M. tuberculosis specimens.
The study also evaluated the following criteria that may
assist TB control programs to identify patients with potentially
cross-contaminated cultures: 1) the patient had a single respi-
ratory specimen positive for M. tuberculosis, regardless of
acid-fast bacilli (AFB) smear status; a single extrapulmonary
body fluid specimen positive for M. tuberculosis, regardless of
AFB status; or a single tissue specimen positive for M. tuber-
culosis without evidence of AFB or granuloma on histologic
examination; 2) the patient had an M. tuberculosis culture-pos-
itive specimen collected >30 days after the collection of an M.
tuberculosis culture-negative specimen, and the isolate had a
unique genotype compared with any previous isolate from the
same patient; 3) the patient had an M. tuberculosis culture-pos-
itive specimen collected >90 days after the start of appropriate,
continuous anti-TB therapy, and the isolate had a unique geno-
type compared with any previous isolate from the same
patient; 4) a caretaker indicated that an M. tuberculosis cul-
ture-positive result was clinically inconsistent; or 5) a labora-
torian indicated that the M. tuberculosis culture-positive result
might be false.
The Massachusetts Department of Public Health Human
Research Review Committee reviewed the protocol and
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waived oversight. Personnel in 24 mycobacteriology laborato-
ries (all the laboratories that were processing specimens for
AFB for persons in Massachusetts at the time) and public
health professionals worked together to identify patients with
potentially cross-contaminated specimens. Persons who were
reported in Massachusetts as possible TB patients and were
reported as having M. tuberculosis–positive cultures between
January 1, 1998, and June 30, 1999, were prospectively
screened. Persons meeting one or more of the criteria were
included in the study.
We reviewed laboratory records to identify potential
sources of cross-contamination, i.e., any M. tuberculosis cul-
ture-positive specimen or laboratory control strain processed,
reprocessed, or subcultured within 2 working days of the
potentially cross-contaminated specimen. For laboratories that
did not record usage dates for control strains, the controls were
designated as potential sources of cross-contamination and
were obtained for genotyping.
The genotype was determined for isolates by IS6110-based
restriction fragment length polymorphism (RFLP) (13) at the
Northeast Regional Genotyping Laboratory, Wadsworth Cen-
ter, Albany, New York. Spoligotyping (14) was used as a sec-
ondary typing method for isolates with five or fewer IS6110
copies. 
Patients with potentially cross-contaminated isolates that
matched organisms from potential sources of contamination
by genotype and patients for whom a DNA fingerprint could
not be produced were investigated. Investigations included
reviews of medical and public health department records,
abstracts from laboratory data, and patient interviews. Because
the criteria would potentially identify not only patients with
false-positive M. tuberculosis cultures that resulted from labo-
ratory cross-contamination but also patients with false-positive
cultures that were caused by other errors as well as true TB
cases, a panel of three TB investigators representing other sen-
tinel sites in the genotyping network reviewed the findings.
The panel judged whether laboratory cross-contamination was
possible, likely, or unlikely and whether the patient had active
TB disease or another clinical diagnosis.
Estimating Costs
The cost of TB misdiagnosis was estimated retrospectively
for patients who had M. tuberculosis culture-positive speci-
mens judged to be possibly or likely caused by laboratory
cross-contamination and who received inappropriate diag-
noses and were treated for TB because of the false-positive
results. (Patients judged to have false-positive M. tuberculosis
cultures caused by other error were not included in the cost
analysis.) Costs for the patient, public sector (local and state
health departments, public health hospital and laboratory, and
county and state correctional facilities), and private sector (pri-
vate physicians, hospitals, and laboratories) incurred specifi-
cally as a result of the cross-contaminated cultures are
included (Table 1). Cost information was collected from the
time of initial misdiagnosis until the patient was no longer fol-
lowed for active TB disease. If patients had other, unrelated
medical costs at the same time, the TB medical officer (EN)
determined which costs could be attributed to cross-contami-
nated cultures.
Data were collected on direct medical and nonmedical
costs for the following: public health department case manage-
ment and administrative support; outpatient visits; TB medica-
tions (started, continued, or changed); directly observed
therapy; tests and procedures (bacteriologic, radiologic, chem-
ical, hematologic, pathologic, immunologic, bronchoscopic,
and biopsy); health department and hospital contact investiga-
tions and diagnostic and treatment services for contacts; and
hospitalizations or transfers to hospital isolation rooms. Indi-
rect and intangible costs were excluded. 
The resources expended for TB care and treatment were
identified from records from these sources: local and state
public health departments; inpatient and outpatient medical
departments; hospital, clinic, and laboratory billing depart-
ments; pharmacies; and mycobacteriology laboratories. We
obtained information about contact investigations from health
department and hospital infection control personnel, and we
asked nurses about public health case management. 
Cost estimates were obtained from several sources
described below; detailed cost information for these estimates
are available upon request. Public health department personnel
costs for case management, administrative support, directly
observed therapy provision, and contact investigations were
estimated by multiplying the sum of annual salaries, fringe
benefits, and overhead (rent, utilities, and supplies) by the
fraction of the year spent on the activity (as estimated by the
health department staff). Costs for providing directly observed
therapy at a correctional facility were estimated by multiplying
hourly salary by the number of hours spent on the activity, as
estimated by the health services administrator. Costs for outpa-
tient visits to health department TB clinics and for tests and
Table 1. Cost inventory for three patients who received misdiagnoses 
of active tuberculosis disease on the basis of laboratory cross-
contamination of Mycobacterium tuberculosis specimensa
Patient Public sectorb Private sectorc
Direct medical costs
TB medications Outpatient visits 
TB medications and PPD
DOT provision
Tests and procedures
Contact investigations
Hospitalizations
Outpatient visits
TB medications and PPD
Tests and procedures
Contact investigations
Hospitalizations
Direct nonmedical 
costs
Case managementd
Overheade 
aTB, tuberculosis; PPD, purified protein derivative of tuberculin; DOT, directly 
observed therapy.
bLocal and state public health departments, public health hospital and laboratory, and 
county and state correctional facilities.
cPrivate physicians, hospitals, and laboratories.
dHealth department case management and administrative support.
eOverhead costs, including rent, utilities, and supplies.TUBERCULOSIS GENOTYPING NETWORK
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procedures at these clinics were based on the TB Division’s
reimbursement to the clinics. Costs of private outpatient visits,
tests, and procedures were estimated on the basis of informa-
tion from provider and laboratory billing departments. Costs
of TB medications and purified protein derivative (PPD) of
tuberculin were based on the TB Division’s expenditures for
TB drugs and PPD for state fiscal years 1999–2000. The
mycobacteriology supervisors estimated costs for mycobacte-
riology procedures at the public health laboratory and one pri-
vate laboratory. Charges for hospitalizations and inpatient tests
and procedures were obtained from patient billing records and
were adjusted to market prices by using Medicare provider-
specific, cost-to-charge ratios. The medical services’ senior
financial analyst estimated the costs for hospitalization at a
correctional facility’s infirmary on the basis of a flat daily bed
rate.
Calculating Cost
Total costs by health-care sector, cost category, and patient
were calculated and reported in 1999 U.S. dollars and rounded
to the nearest whole dollar. 1998 dollars were adjusted by
using the Consumer Price Index Medical Care component.
Costs were not discounted because all costs occurred within 1
year of diagnosis.
Results
Rate of TB Misdiagnosis
Between January 1, 1998, and June 30, 1999, 342 of the
persons reported as possible TB case-patients in Massachu-
setts had M. tuberculosis positive cultures; of these, 5 (1.5%)
had cultures judged to be cross-contaminated in the laboratory.
Three (0.9% of 342) of the five persons received misdiagnoses
for active TB disease on the basis of the results (Table 2). Each
case had been reported as a verified case of TB for national
surveillance, but the status was revoked when information
from this investigation became available.
Despite their positive cultures, two patients with cross-
contaminated cultures were not treated for active TB disease,
largely because their physicians did not believe a TB diagnosis
was clinically consistent. The mycobacteriology laboratory
that processed one patient’s specimen questioned the result
and performed in-house RFLP typing that confirmed labora-
tory cross-contamination. Both patients were informed about
the false-positive results and reassured about the findings.
Costs by Health-Care Sector
The costs of caring for the three patients whose misdiag-
noses and treatment for active TB resulted from laboratory
cross-contamination are summarized in Table 3. The total was
estimated to be $32,618 in 1999 U.S. dollars. Ninety-seven
percent of costs ($31,552) occurred within the public sector:
$14,319 at the public hospital, $9,024 within the correctional
system, $7,075 to local and state public health departments,
and $1,134 to the public health laboratory. Three percent
($949) occurred within the private sector: $381 at hospitals,
$316 from laboratories, and $252 for physicians. The patient
incurred <1% of the total costs—$118 that went for TB medi-
cations.
Costs by Category
Across all sectors, hospitalizations (daily inpatient bed rate
and differential for transfer to isolation room) accounted for
59% ($19,348) of total costs. This category was followed by
TB medications and PPD ($68 inpatient/$5,774 outpatient),
tests and procedures ($3,046 inpatient/$1,695 outpatient), per-
sonnel time for directly observed therapy provision ($1,376),
outpatient visits ($686), personnel time for health department
case management and administrative support ($615), and per-
sonnel time for contact investigations ($10). In all, $22, 462
(69%) of the total cost came from hospitalizations and inpa-
tient TB medications, tests, and procedures.
Costs by Patient
The total costs for health care for patients 1, 2, and 3 were
$1,033, $10,279, and $21,306, respectively. The average cost
per patient was $10,873. Sixty-seven percent of the costs for
patient 1 occurred in the private sector: $369 at the hospital,
$253 for physicians, and $67 from the laboratory; 22% ($226)
by public health departments for case management and admin-
istrative support; and 11% ($118) by the patient for TB medi-
cations. For patient 2’s care, 97% of the costs occurred in the
public sector: $7,809 at the public health hospital, $1,491 to
health departments, and $720 to the public health laboratory.
Three percent of the costs occurred in the private sector: $248
from the laboratory and $11 at the hospital. All costs for
patient 3 were within the public sector with $9,024 to county
and state correctional facilities, $6,510 at the public health
hospital, $5,358 to public health departments, and $414 to the
public health laboratory.
Discussion
Rate of TB Misdiagnosis
In Massachusetts, the rate of patients having false-positive
cultures resulting from laboratory cross-contamination of M.
tuberculosis  specimens was 1.5% of the culture-confirmed
possible TB cases. This rate is within the range demonstrated
in other population-based studies (1–3,7–11). In our study,
60% of the patients with cross-contaminated cultures received
misdiagnoses and were treated for active TB disease, yielding
a rate of TB misdiagnoses caused by laboratory cross-contam-
ination of 0.9% of patients with culture-confirmed TB. These
findings corroborate those of Burman and Reves, who esti-
mated that two thirds of patients with false-positive cultures
are treated for active TB (4).
Costs of Misdiagnosis
For the three patients, the costs of TB false diagnoses from
laboratory cross-contamination fell largely to the public healthEmerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1267
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Table 2. Characteristics of patients who received misdiagnoses of active tuberculosis disease resulting from laboratory cross-contamination of 
Mycobacterium tuberculosis specimensa
Characteristics Patient 1 Patient 2 Patient 3
Demographic information
Age at diagnosis (yrs) 59 29 38
Sex Female Male Male
Clinical information
Site of disease Lymphatic Pulmonary Soft tissue, right index finger
Symptoms when examined  Chronic cough, weight loss, increasing 
fatigue, night sweats (Sept 1998)
Abdominal discomfort, diarrhea, flank 
pain, high fever, cough with blood, 
delirium tremens (Nov 1998)
Infection of right index finger,b great 
pain, lymphangitic streaks up arm (Aug 
1998)
Radiology, initial CAT scan: lymphadenopathy, densities 
in upper lobes suggestive of infiltration 
or scarring
Chest x-ray: right lower lobe infiltrate, 
improved with intravenous ceftriaxone
X-ray right hand: swelling over right 
index DIP and PIP joints; chest x-ray: 
normal
Pathology Lymph node biopsy positive for lym-
phoma, chemotherapy started
Not applicable Not done/missing
TST result Negative Negative Negative
Underlying conditions and TB 
risk factors
History of Hodgkin lymphoma and treat-
ment for active TB disease in 1995,c 
non–U.S.-born
History of chronic alcohol abuse and 
cocaine use
HIV positive, history of IVDU and incar-
ceration
TB health care
TB health-care provider Private physician Public health department TB clinic Public health department TB clinic, cor-
rectional facility clinic
Type of TB therapy Self-administered Daily DOT by public health nurse Daily DOT by correctional facility staff
Duration of TB therapy <1 month (started Dec 1998) <2 months (started Dec 1998) 11 months (treated for 2 weeks in Oct 
1998, restarted December 1998)
Hospitalization(s) following 
TB diagnosis
5 days in private hospital (Jan 1999) 
with increasing respiratory distress, 
treated for community acquired pneumo-
nia, died of presumed progression of 
non–Hodgkin lymphoma
11 days in private hospital with acute 
gastritis secondary to alcohol abuse (Jan 
1999), TB therapy discontinued second-
ary to increased LFTs; 15 days at public 
health hospital for TB management; TB 
ruled out
8 days at public health hospital to start 
anti-TB therapy and rule out pulmonary 
and bone involvement (Oct 1998); 5 days 
in correctional facility infirmary
Contact investigations 
By public health department  Not done One household contact identified, 
TST-negative
Not done
By hospital infection control  Not done Not done Not done
Information on cross-contami-
nated specimen 
Specimen type Right inguinal lymph node tissue Sputum Swab of finger cellulitis 
AFB smear result Negative Negative Negative
AFB culture result 1 colony at 60 days (reported Dec 1998), 
sensitive to INH, RIF, EMB, Strep (PZA 
not tested)
1 colony at 40 days (reported Dec 
1998), slightly resistant to INH
“Rare” colonies at 42 days (reported Sept 
1998), INH resistant
NTGSN IS6110 
RFLP analysis
10-band pattern (reported April 1999), 
RFLP match to an isolate from a known 
TB patient 
9-band pattern (reported April 1999), 
RFLP match to an isolate from a known 
TB patient
16-band pattern (reported Oct 1999), 
RFLP match to laboratory control strain 
H37Ra
Case appraisal resultsd
Case diagnosis Lymphoma, nosocomial bacterial pneu-
monia
Community-acquired pneumonia Streptococcus cellulitis
Did laboratory cross-con-
tamination occur?
Likely Likely Likely
aTST, tuberculin skin test; TB, tuberculosis; CAT, computerized axial tomograpy; AFB, acid-fast bacilli; NTGSN, National Tuberculosis Genotyping and Surveillance Network; RFLP, 
restriction fragment length polymorphism; INH, isoniazid; RIF, rifampin; EMB, ethambutol; Strep, streptomycin; PZA, pyrazinamide; DOT, directly observed therapy; LFTs, liver 
function tests; DIP, distal interphalangeal; PIP, proximal interphalangeal; and IVDU, intravenous drug use.
bInfection of right index finger ultimately resulting in amputation; specimen grew Streptococcus Group A.
cPatient treated for active TB disease in 1995, although there was not enough evidence to verify the case for national surveillance.
dCase appraisals performed by a panel of three TB investigators representing other NTGSN sentinel sites.TUBERCULOSIS GENOTYPING NETWORK
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and correctional system. Hospitalizations and inpatient tests,
procedures, and TB medications accounted for 69% of total
health-care sector costs. This finding is consistent with the
findings of Brown et al., who demonstrated that inpatient care
accounted for 60% of TB health-care expenditures in 1991
even though TB is considered an ambulatory disease (15).
Moreover, most of the inpatient costs were for the care of
patients 2 and 3, whose underlying circumstances contributed
to their hospitalization.
The costs of TB misdiagnosis varied greatly between the
three patients (range $1,033–$21,306) and reflected their
unique clinical circumstances and treatment courses. Patient 1
had the lowest costs of the three patients. She was treated with
anti-TB therapy for only a few weeks before she died of prob-
able lymphoma. Because extrapulmonary TB was diagnosed,
no contact investigation was conducted.
Patient 2, with cost of care totaling $10,279, completed <2
months of anti-TB therapy. It was discontinued secondary to
elevated liver function tests. The physician found no clinical
correlation for a TB diagnosis and did not restart treatment,
thus averting additional costs for a full 6-month course of TB
therapy. Although pulmonary TB was diagnosed, the patient
was AFB smear-negative, so only a limited contact investiga-
tion was performed: one household contact was tested.
The greatest cost ($21,306) was for patient 3. The patient’s
false-positive culture was discovered only as a result of geno-
typing through the TB genotyping network, and the patient
completed 11 months of an intended 12-month course of anti-
TB therapy. A diagnosis of single drug-resistant TB and an
HIV-positive status further complicated his care. Because
extrapulmonary TB was diagnosed, no contact investigation
was conducted.
The average cost per patient was $10,873; however,
because of the small sample size (n=3), we cannot conclude
whether this is a representative estimate of the average cost per
TB misdiagnosis. Since two of the patients were hospitalized
in a public, long-term care facility rather than an acute-care
hospital, the costs were probably much lower than they could
have been. However, these preliminary findings demonstrate
that substantial costs can result from misdiagnoses caused by
laboratory cross-contamination. Additional research with a
larger sample size is warranted.
Limitations to the Study
This study included only three patients and did not include
estimates of indirect and intangible costs. Since these costs
largely affect the patient, we likely underestimated the effects
of TB misdiagnosis on patients. Although the consequences
were not collected formally, the patients had negative indirect
or intangible consequences attributable to the misdiagnoses.
The hospitalization of patient 2 and patient 3 represented 13
and 15 days of lost productivity, respectively. In addition,
patient 3 underwent a painful bone marrow biopsy to rule out
TB involvement of the bone. At the county correctional facil-
ity, patient 3 was placed in solitary confinement after testing
positive for an illegal substance because of a false-positive
reaction from rifampin. The patients likely experienced emo-
tional anxiety, fear, stress, and stigmatization; they were also
exposed to unnecessary treatment with potential risks for
adverse effects (which did not occur).
Another limitation is that personnel time costs were
derived from staff’s retrospective estimates of the time
involved in various activities, which could have resulted in
error. We excluded payers such as Medicare, Medicaid, or pri-
vate insurers from our study. We showed where costs were
incurred within the health-care sectors, but we did not address
who actually paid for the resources. This is another area for
future research.
Table 3. Estimated costs for three patients who received misdiagnoses of active tuberculosis disease on the basis of laboratory cross-contamina-
tion of Mycobacterium tuberculosis specimensa,b
Cost category
Estimated costs (U.S.$)
Patient 1 Patient 2 Patient 3 Total
Case managementc 226 288 100 614
Outpatient visits 186 58 443 687
TB medications and PPD 175 606 5,061 5,842
DOT provisiond 0 508 868 1,376
Tests and procedures 134 1,904 2,703 4,741
Contact investigationse 01 0 0 1 0
Hospitalizationsf 312 6,905 12,131 19,348
Total 1,033 10,279 21,306 32,618
aCosts reported in 1999 U.S. dollars, rounded to the nearest whole dollar. Costs adjusted to 1999 dollars by using the Medical Care group of the Consumer Price Index.
bTB, tuberculosis; PPD, purified protein derivative of tuberculin; DOT, directly observed therapy.
cPersonnel time for health department case management and administrative support.
dPersonnel time to provide directly observed therapy
ePersonnel time to perform contact testing.
fDaily inpatient bed rate and differential for transfer to isolation room.Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1269
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Averting Costs of TB Misdiagnoses
This study demonstrates that substantial financial burden
can be placed on the health-care system as a result of labora-
tory cross-contamination. The study also underscores the need
for primary prevention of laboratory cross-contamination and
the timely recognition of patients who have cross-contami-
nated M. tuberculosis cultures.
Investigators have recommended actions that laboratories,
clinicians, and health departments can take to minimize the
negative consequences of false-positive M. tuberculosis cul-
tures: standardizing laboratory procedures, establishing sur-
veillance for identifying false-positive M. tuberculosis
cultures, and prospectively screening for patients who may
have false-positive cultures (1,4–6,9). We found that clinicians
may play an important role in averting the costs associated
with TB misdiagnosis resulting from laboratory cross-contam-
ination. Of the five patients with cross-contaminated M. tuber-
culosis cultures, two were not diagnosed with TB because
their physicians did not believe the false-positive results. Anti-
TB therapy was discontinued after only 2 months for patient 2
because his TB care provider did not believe a TB diagnosis
was clinically consistent. Thus interventions may be targeted
at physicians who submit samples that test positive for M.
tuberculosis.
Selective genotyping of isolates from patients who have
single positive M. tuberculosis cultures may also play a role in
limiting the costs of TB misdiagnosis resulting from labora-
tory cross-contamination. For two of the three study patients
who received misdiagnoses for active TB disease, neither the
clinicians nor the laboratory personnel reported having sus-
pected that the M. tuberculosis culture-positive result might be
false; the errors were only detected through routine genotyping
by the TB genotyping network. 
Actions taken to minimize the negative consequences of
false-positive M. tuberculosis cultures would require health-
care resources. Even so, the costs of implementing these
actions would likely be less than the costs of misdiagnosis,
especially when intangible costs to the patient are considered.
Increased efforts to avoid laboratory cross-contamination and
to detect its occurrence as quickly as possible could help pre-
vent unnecessary and potentially dangerous treatment, anguish
for the patient, and financial costs to the health-care system. 
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